Everything below concerns GLP-1 receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | Lyophilised solid form |
| Solubility | pH dependent; low near pI | Minimum close to pH 5.4 |
| Storage temperature | -20 C solid; 2-8 C solution | Protect from light |
| Isoelectric point | approx. pH 5.4 | Controls solubility minimum |
| Common analytical method | RP-HPLC with mass detection | Purity and identity checks |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
== Comparison to SSRIs == As SNRIs were developed more recently than SSRIs, there are relatively few of them. However, the SNRIs are among the most widely used antidepressants today. In 2009, Cymbalta and Effexor were the 11th- and 12th-most-prescribed branded drugs in the United States, respectively. This translates to the 2nd- and 3rd-most-common antidepressants, behind Lexapro (escitalopram), an SSRI. In some studies, SNRIs demonstrated slightly higher antidepressant efficacy than the SSRIs (response rates 63.6% versus 59.3%). However, in one study escitalopram had a superior efficacy profile to venlafaxine. SSRIs do not significantly increase norepinephrine, which is where SNRIs may be used for a greater variety of conditions involving norepinephrine, such as chronic pain disorders. Some additional side effects noted with SNRIs can include increased heart rate and blood pressure. Overall, most patients are able to tolerate both similarly, and their choice depends more on their symptoms, medical history, and previous response to antidepressants.
Selegiline was approved for Parkinson's disease by the FDA in 1989. It had been known since the mid-1960s that high doses of deprenyl had psychostimulant effects. Selegiline was first shown to metabolize into levomethamphetamine and levoamphetamine in humans in 1978. The involvement of these metabolites in the effects and side effects of selegiline has remained controversial and unresolved in the decades afterwards. In any case, concerns about these metabolites have contributed to the development of newer MAO-B inhibitors like rasagiline and safinamide that lack such metabolites. The catecholaminergic activity enhancer (CAE) effects of selegiline became well-characterized and distinctly named in 1994. These effects had been observed much earlier, dating back to the 1960s and 1970s, but were not properly distinguished from the other actions of selegiline, like MAO-B inhibition, until the 1990s. More potent, selective, and/or expansive monoaminergic activity enhancers (MAEs), like phenylpropylaminopentane (PPAP) and benzofuranylpropylaminopentane (BPAP), were derived from selegiline and other compounds and were first described in 1988 and 1999, respectively. These drugs had been proposed for potential treatment of psychiatric disorders like depression as well as for Parkinson's disease and Alzheimer's disease, but were never developed or marketed. In the 1990s, J.
Promising innovations relating to global challenges are reported: LAION releases a first version of BUD-E, a fully open source voice assistant (8 Feb), Minesto's Dragon 12 underwater tidal kite turbines are demonstrated successfully, connected to the Faroe Island's power grid (11 Feb), rice grains as scaffolds containing cultured animal cells are demonstrated (14 Feb), an automatic waste sorting system (ZenRobotics 4.0) that can distinguish between over 500 waste categories is released (15 Feb), researchers describe an AI ecosystem interface of foundation models connected to many APIs as specialized subtask-solvers (16 Feb), precision fermentation-derived beta-lactoglobulin is released as a substitute for whey protein amid growth of a nascent animal-free dairy industry (19 Feb), researchers describe an approach for an optical disk with petabit capacity (21 Feb).
== O == Obex The point in the brainstem where the fourth ventricle narrows to become the central canal of the spinal cord. Used as an anatomical landmark in neuroanatomy. Occipital lobe The rearmost lobe of the cerebral cortex, primarily responsible for visual processing, including interpretation of color, motion, and spatial orientation. Ocular dominance A preference of neurons in the visual cortex for input from one eye over the other. Studied extensively in visual development and plasticity. Oculomotor nerve (Cranial Nerve III) A cranial nerve that controls most of the eye's movements, including those of the eyelid and pupil constriction. Damage may result in diplopia or ptosis. Olfaction The sense of smell, mediated by receptors in the olfactory epithelium and processed in the olfactory bulb and related brain regions. Olfactory bulb The first brain structure to process olfactory (smell) information. Receives input from sensory neurons in the nasal cavity and sends projections to the olfactory cortex and limbic system. Olfactory cortex A region of the brain involved in odor identification and perception. Includes the piriform cortex and parts of the amygdala and entorhinal cortex. Olfactory nerve (Cranial Nerve I) The first cranial nerve, responsible for transmitting smell information from the nose to the brain. Oligodendrocyte A type of glial cell in the central nervous system that forms the myelin sheath around axons, enabling rapid signal conduction.
Sources: en.wikipedia.org
=== Biological slug mucus === Mucus from gastropods is composed of a combination of water and glycoproteins, enzymes, and trace amounts of metal ions. Mucin glycoproteins, like achacin and glycosaminoglycans (GAGs) like hyaluronic acid are the primary components of mucus, contributing to its antimicrobial properties. Amino groups interact with the sulfate and carboxyl groups found in the glycosaminoglycans to promote bonding and hydrophobic interactions during gel formations. Other molecules like allantoin, or 5-ureidohyantoin, can be found in slug mucus to prompt cell proliferation and wound healing, as well as collagen synthesis, respectively. Significant amounts of zinc, iron, copper, and manganese metal ions are typically found in the chemical composition of slug mucus.
It contained an immense rectangular hall, 55 metres long, 25 wide, and 15 metres high, supported by forty slender cast-iron columns, and was originally covered with a glass roof one thousand square metres in size. The building suffered from technical problems, and was closed entirely in 1965. It was extensively remodelled between 1991 and 1994 and reopened in its present form. The great central hall, kept in its same form but enlarged during the modernisation, is devoted to the presentation of marine animals on the lower sides, and, on a platform in the centre, a parade of full-size African mammals, including a rhinoceros originally presented to King Louis XV in the 18th century. On the garden side is another hall, in its original size, devoted to animals which have disappeared or are in danger of extinction.
During the development of Half-Life 2, Newell spent months developing Steam, a digital distribution service for games. By 2011, Steam controlled between 50% and 70% of the market for downloaded PC games and generated most of Valve's revenue. At a technology conference in Seattle that year, Newell argued that software piracy was best addressed by offering a superior option rather than pursuing anti-piracy technology. He cited Steam's success in Russia, where piracy is rife, as an example. Following the difficult development of Half-Life 2, Newell said he became "obsessed" with improving Valve's work-life balance.In 2007, Newell expressed his displeasure over developing for game consoles, saying that developing processes for Sony's PlayStation 3 was a "waste of everybody's time". On stage at Sony's keynote at E3 2010, he acknowledged his criticism but discussed the open nature of the PlayStation 3 and announced a port of Portal 2, remarking that with Steamworks support it would be the best version for any console. Newell also criticized the Xbox Live service, referring to it as a "train wreck", and Windows 8, calling it a threat to the open nature of PC gaming. At the 2013 LinuxCon, Newell said the Linux operating system and open source development were "the future of gaming". He accused the proprietary systems of companies such as Microsoft and Apple of stifling innovation through slow certification processes.
== Nasal drugs == The area of intranasal medication delivery provides a huge opportunity for research – both for specifically developed pharmaceutical drugs designed for intranasal treatment, as well as for investigating off-label uses of commonly available generic medications. Steroids, and a large number of inhalational anaesthetic agents are being used commonly. The recent developments in intranasal drug delivery systems are prodigious. Peptide drugs (hormone treatments) are also available as nasal sprays, in this case to avoid drug degradation after oral administration. The peptide analogue desmopressin is, for example, available for both nasal and oral administration, for the treatment of diabetes insipidus. The bioavailability of the commercial tablet is 0.1% while that of the nasal spray is 3-5% according to the SPC (Summary of Product Characteristics). Intranasal calcitonin, calcitonin-salmon, is used to treat hypercalcaemia arising out of malignancy, Paget's disease of bone, post menopausal and steroid induced osteoporosis, phantom limb pain and other metabolic bone abnormalities, available as Rockbone, Fortical and Miacalcin Nasal Spray. GnRH analogues like nafarelin and busurelin are used for the treatment of anovulatory infertility, hypogonadotropic hypogonadism, delayed puberty and cryptorchidism. Other potential drug candidates for nasal administration include anaesthetics, antihistamines (Azelastine), antiemetics (particularly metoclopramide and ondansetron) and sedatives that all benefit from a fast onset of effect.
Haji-Sheikh, Haji-Sheikh & Naples (2026) present new cranial endocasts of Smilodon fatalis, and calculate that the range of brain endocast volumes of the studied species overlaps with the published range of brain volumes of modern lions. Evidence of utility of CT and MicroCT scans in determining the condition of tooth sockets in skulls of Smilodon fatalis from the La Brea Tar Pits, as well as in determining whether the canines of the studied specimens were correctly associated and correctly seated in tooth sockets during restoration of the skulls, is presented by Haji-Sheikh, Haji-Sheikh & Naples (2026). Schmökel, Del Chicca & Hagen Argudin Pina (2026) identify pathologies in three vertebrae of Smilodon fatalis from the La Brea Tar Pits, interpreted as consistent with the diagnosis of a spinal nerve tumor. Fernández-Jalvo et al. (2026) identify tooth marks of Smilodon on bones of Toxodon, Notiomastodon, Doedicurus, Glossotherium and Lestodon from the Pleistocene strata from the Salto de Piedra site (Argentina). A felid mandible interpreted as the most definitive fossil material of Homotherium latidens from Anatolia reported to date is described from the Burdur Basin (Turkey) by Yavuz et al. (2026). Nikolskiy et al. (2026) report the discovery of canines of Homotherium in the late Pleistocene strata from Suruktakh in the Kolyma River basin and from the Bolshoy Lyakhovsky Island (Russia), comfirming presence of members of this genus in northeastern Siberia approximately 41,500–37,500 years ago.
Sources: en.wikipedia.org
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.
Mass spectrometry, usually electrospray ionisation coupled to liquid chromatography, gives an observed mass for comparison with the theoretical value. Peptide mapping after digestion provides complementary sequence-level confirmation.
Short exposure during weighing and handling is generally tolerated, but prolonged storage above refrigerated conditions raises the risk of deamidation, oxidation, and aggregation. The rate depends on pH, buffer composition, and concentration.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.